# Ansbert Gadicke

> Ansbert Gadicke is a Series A investor at MPM Capital backing Biotechnology and Pharmaceutical. See 12 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [MPM Capital](https://shizune.co/investors/profile/mpm-capital)
- Location: Cambridge, United States
- Total investments: 12
- Last investment: Sep 2025
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/ansbert-dr-gadicke-2437b5/

Ansbert Gadicke is a Series A investor at MPM Capital in Cambridge focused on Biotechnology and Pharmaceutical. Ansbert Gadicke, M.D., co-founded MPM in 1997 with his partner Luke Evnin. Over many years the MPM team they have led has been the inspiration and driving force behind building leading biopharmaceutical companies such as Biomarin (BMRN), CoStim Pharmaceuticals (acquired by Novartis:NVS), Epizyme (EPZM), Pacira (PCRX), Pharmasset (acquired byGilead:GILD) and Radius (RDUS). MPM believes that these companies are some of the biggest successes in biotech history-companies that ultimately resulted in helping thousands of patients live longer and with vastly improved lives. Ansbert was the lead investor and has served on the boards of several of MPM’s most successful investments including BioMarin, Idenix, Pharmasset and Radius.Prior to the launching of MPM’s venture investing activities, Ansbert led MPM’s Advisory and Investment Banking business, and prior to that he was at The Boston Consulting Group in their Boston office in the Health Care Group. Ansbert was first to study expression of HPV proteins 16 and 18 in human cancer cells and to characterize their cDNAs (which were then used by Pharma for vaccine developments) while under the leadership of Professor Harald zur Hausen, who received the Nobel Prize in Physiology or Medicine in 2008.Ansbert’s commitment to drug discovery and curing disease inspires his work and that of his team in building leading biotechnology companies at MPM, as well as his commitments outside of MPM. He is a member of the Board of Fellows of Harvard Medical School and the Research Advisory Council of Massachusetts General Hospital.Ansbert received an M.D. from J.W. Goethe University in Frankfurt. He held research positions in biochemistry and molecular biology at the Whitehead Institute at MIT and the Biochemistry Department at Harvard University, and has published in leading scientific journals such as Nature and Cell.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 10 | 83% |
| Pharmaceutical | 5 | 42% |
| Medical | 4 | 33% |
| Therapeutics | 4 | 33% |
| Health Care | 3 | 25% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 42% |
| Series B | 3 | 25% |
| Series C | 2 | 17% |
| Series D | 1 | 8% |
| Post-IPO Secondary | 1 | 8% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 9 | 75% |
| Canada | 1 | 8% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Reunion Neuroscience | Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depressionand other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications. | $133M | Series A | Sep 16, 2025 |  |
| ElevateBio | ElevateBio is an operator of a portfolio of cell and gene therapy companies intended to develop, manufacture, and commercialize life-transforming medicines.The company creates a portfolio through partnerships with the world's innovative scientists and inventors as well as it created a centralized facility that integrates all the elementsthat translate cell and gene therapy R&D into commercially viable therapies quickly and efficiently, enabling patients to get medical products to treat severe diseases.Vikas Sinha, Mitchell Finer, and David Hallal co-founded ElevateBio in Cambridge, Massachusetts in 2017. | $401M | Series D | May 24, 2023 |  |
| ReNAgade Therapeutics | ReNAgade Therapeutics focuses on the boundless potential of RNA therapeutics to treat disease. RNA delivery systems with a comprehensive RNA platform that allows for an all-RNA system for coding, editing, and gene insertion to produce new medications. | $300M | Series A | May 23, 2023 |  |
| Orna Therapeutics | Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Orna’s proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions. | $221M | Series B | Aug 16, 2022 |  |
| Orna Therapeutics | Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Orna’s proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions. | $80M | Series A | Feb 24, 2021 |  |
| ITeos Therapeutics | ITeos Therapeutics is a private biotechnology company targeting the metabolism of the tumor microenvironment to develop small molecule immunomodulators for cancer treatments. iTeos is building its activities upon the unparalleled expertise of the Ludwig Cancer Research (LICR) – a world-class Research Institute in the fields of tumor immunology,therapeutic cancer vaccines, cancer biology, and translational medicine in cancer.iTeos endeavors to develop small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints (e.g. anti-CTLA4, anti-PD1, and anti-PDL1 antibodies). | $75M | Series B | Jun 20, 2018 |  |
| Raze Therapeutics | Raze Therapeutics is leading the discovery and development of a new class of oncology therapeutics that target key metabolic pathways. Raze is advancing a pipeline of therapeutics based on new biological insights into how cancer cells reprogram metabolism to activate central anabolic processes essential for tumors to grow and survive. | $24M | Series A | Oct 14, 2014 |  |
| Sideris Pharmaceuticals | Sideris Pharmaceuticals Inc. is a privately held biopharmaceutical company that is focused on development of therapeutics for the treatment of transfusion-related iron overload. The company’s operations include facilities in Boston, MA, and in Gainesville, FL. | $32M | Series A | Oct 22, 2013 |  |
| Verastem Oncology | Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. Its portfolio consists of small molecule kinase inhibitors that inhibit critical signaling pathways, which promote cancer cell survival and tumor growth. | $20M | Series C | Nov 11, 2011 |  |
| Verastem Oncology | Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. Its portfolio consists of small molecule kinase inhibitors that inhibit critical signaling pathways, which promote cancer cell survival and tumor growth. | $32M | Series B | Jul 14, 2011 |  |

10 of 12 investments shown.

## Co-investors
- [Astellas Venture Management](https://shizune.co/investors/profile/astellas-venture-management) — VC Fund, 3 deals together
- [F2 Ventures](https://shizune.co/investors/profile/f2-ventures) — VC Fund, 3 deals together
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund, 2 deals together
- [Cardinal Partners](https://shizune.co/investors/profile/cardinal-partners) — VC Fund, 2 deals together
- [Longwood Fund](https://shizune.co/investors/profile/longwood-founders-fund) — VC Fund, 2 deals together
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 2 deals together

## About MPM Capital

VC Fund · Cambridge, United States

MPM Capital is a healthcare investment firm that invests in companies developing therapeutic technologies in oncology. The company invests in life sciences companies that seek to cure diseases by translating science into clinical outcomes. The company prefers to invest in the biotechnology, healthcare, and life sciences sectors.

5 contacts available at MPM Capital.

| Name | Title | Profile |
| --- | --- | --- |
| David P. Ryan | Medical and Scientific Advisor | https://shizune.co/investors/profile/david-p-ryan |
| Detlev Biniszkiewicz | Executive Partner | https://shizune.co/investors/profile/detlev-biniszkiewicz |
| Uciane Scarlett | Principal | https://shizune.co/investors/profile/uciane-scarlett |
| Ansbert Gadicke | Managing Director and Co-Founder | https://shizune.co/investors/profile/ansbert-k-gadicke |
| Bard Geesaman | Managing Director | https://shizune.co/investors/profile/bard-geesaman |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Ansbert Gadicke invest in?

Ansbert Gadicke invests primarily in Biotechnology, Pharmaceutical and Medical startups, most often at Series A and Series B stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Ansbert Gadicke last invest?

The most recent investment recorded for Ansbert Gadicke closed in Sep 2025. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co